{"id":420877,"date":"2025-09-24T00:00:00","date_gmt":"2025-09-24T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algocv0012-2025-biopharma-heart-failure-current-treatment-treatment-algorithms-claims-data-analysis-heart-failure-with\/"},"modified":"2026-04-19T11:10:15","modified_gmt":"2026-04-19T11:10:15","slug":"algocv0012-2025-biopharma-heart-failure-current-treatment-treatment-algorithms-claims-data-analysis-heart-failure-with","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algocv0012-2025-biopharma-heart-failure-current-treatment-treatment-algorithms-claims-data-analysis-heart-failure-with\/","title":{"rendered":"Heart Failure &#8211; Current Treatment &#8211; Treatment Algorithms: Claims Data Analysis &#8211; Heart Failure with Preserved Ejection Fraction (US)"},"content":{"rendered":"<p>Heart failure with preserved ejection fraction (<abbr data-abbreviation-entity=\"6460\" title=\"heart failure with preserved ejection fraction\">HFpEF<\/abbr>) accounts for approximately half of all chronic heart failure cases. Even though physicians\u2019 understanding of the disease\u2019s pathophysiology has improved, pharmacological treatments with proven outcomes and benefits have been elusive. Drug treatment focuses primarily on managing the comorbidities, and first-line treatment typically consists of <abbr data-abbreviation-entity=\"5703\" title=\"renin-angiotensin-aldosterone system\">RAAS<\/abbr> inhibitors, beta blockers, and diuretics. The addition of a second-line treatment may be required to better manage the disease. The standard of care for <abbr data-abbreviation-entity=\"6460\" title=\"heart failure with preserved ejection fraction\">HFpEF<\/abbr> is changing with the availability of the Entresto (sacubitril \/ valsartan) and <abbr data-abbreviation-entity=\"10361\" title=\"sodium-glucose co-transporter\">SGLT<\/abbr>-2 inhibitors for this population. This report provides important insight into how these agents are used in the management of <abbr data-abbreviation-entity=\"6460\" title=\"heart failure with preserved ejection fraction\">HFpEF<\/abbr> and how practices are evolving.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What patient shares do key therapies and brands garner by line of therapy in newly diagnosed <abbr data-abbreviation-entity=\"6460\" title=\"heart failure with preserved ejection fraction\">HFpEF<\/abbr> patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed <abbr data-abbreviation-entity=\"6460\" title=\"heart failure with preserved ejection fraction\">HFpEF<\/abbr> patients?<\/li>\n<li>How have <abbr data-abbreviation-entity=\"10361\" title=\"sodium-glucose co-transporter\">SGLT<\/abbr>-2 inhibitors been integrated into the treatment algorithm, and what are their sources of business?<\/li>\n<li>What percentage of <abbr data-abbreviation-entity=\"6460\" title=\"heart failure with preserved ejection fraction\">HFpEF<\/abbr> patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?<\/li>\n<li>What percentage of <abbr data-abbreviation-entity=\"6460\" title=\"heart failure with preserved ejection fraction\">HFpEF<\/abbr> patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated patients?<\/li>\n<\/ul>\n<p><strong>Product description<\/strong><\/p>\n<div>\n<div>\n<div>\n<p>Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:<\/p>\n<\/div>\n<div>\n<ul class=\"BulletListStyle1 SCXW152425059 BCX0 round-bullets\">\n<li>Understand patient flow between lines of therapy.<\/li>\n<li>Evaluate your brand share against competitors.<\/li>\n<li>Accurately assess your source of business.<\/li>\n<li>Quantify opportunities at different stages of the treatment algorithm.<\/li>\n<\/ul>\n<p><strong>Product enhancement<\/strong><\/p>\n<p>Treatment Algorithms: Claims Data Analysis leverages Clarivate\u2019s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<p><strong>Markets covered:<\/strong> United States<\/p>\n<p><strong>Key companies: <\/strong>Pfizer, Merck &#038; Co., Novartis, <abbr title=\"GlaxoSmithKline\">GSK<\/abbr>, AstraZeneca, Johnson &#038; Johnson Innovative Medicine, Eli Lilly, Boehringer Ingelheim, Amgen<\/p>\n<p><strong>Key drugs:<\/strong> <abbr data-abbreviation-entity=\"5680\" title=\"angiotensin-converting enzyme\">ACE<\/abbr> inhibitors, <abbr title=\"angiotensin II receptor blocker\">ARB<\/abbr>s, beta blockers, <abbr data-abbreviation-entity=\"7152\" title=\"mineralocorticoid receptor antagonist\">MRA<\/abbr>s, diuretics, <abbr data-abbreviation-entity=\"5686\" title=\"calcium channel blocker\">CCB<\/abbr>s, nitrates, Entresto (sacubitril \/ valsartan), <abbr data-abbreviation-entity=\"10361\" title=\"sodium-glucose co-transporter\">SGLT<\/abbr>-2 inhibitors<\/p>\n<p><strong>Key feature: <\/strong>Dashboard featuring interactive visuals, easy navigation, and expanded analyses<\/p>\n","protected":false},"template":"","class_list":["post-420877","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-cardiovascular","biopharma-therapy-areas-heart-failure","biopharma-product-current-treatment","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/420877","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":3,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/420877\/revisions"}],"predecessor-version":[{"id":575733,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/420877\/revisions\/575733"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=420877"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}